In Mexico, the rapid proliferation of Ozempic and Wegovy medications, which are based on semaglutide and belong to the group of GLP-1 receptor agonists, is outpacing health regulations, leading to significant risks associated with self-medication, illegal purchases, aesthetic use, and products of uncertain origin. Health specialists warn that while these drugs have shown great potential in transforming diabetes management and aiding weight reduction in selected patients, their official use is strictly for individuals with diabetes under stringent medical supervision.

Alejandra Solís Alarcón, a clinical nutrition expert, emphasized that despite the drugs being effective for diabetes treatment, their authorized usage is not for general weight loss but rather for patients with specific complications. The increasing trend of individuals consuming these medications indiscriminately heightens concerns over their safety and the potential for adverse effects without proper medical guidance. The situation calls for enhanced regulation and public awareness to mitigate the risks associated with self-medication.

The misuse of these drugs for weight loss could lead to serious health repercussions and reflects a broader issue concerning the accessibility of medications without appropriate oversight. As the demand for weight loss solutions grows, it is imperative to address these challenges with stricter regulations and education for healthcare providers and patients to ensure safe usage, thereby safeguarding public health.